Rituxan

RITUXAN, on which we partner with Genentech and Roche, saw 6 percent growth in U.S. sales in 2011. RITUXAN remains the standard of care for non-Hodgkin's lymphoma, and is also approved for use in chronic lymphocytic leukemia (CLL), moderately to severely active rheumatoid arthritis (RA) and ANCA-associated vasculitis.